Last updated: August 18, 2026
MUSE is a transurethral alprostadil product for erectile dysfunction. Its commercial position has deteriorated because oral PDE5 inhibitors became generic, while MUSE retains higher administration complexity, lower convenience, and limited physician adoption. The product has no meaningful current regulatory exclusivity, and public companies no longer report MUSE revenue as a distinct material line item. Its economic value is primarily as a niche branded product or legacy commercial asset rather than a growth platform.
What is MUSE and how does it work?
MUSE is the brand name for alprostadil delivered as a urethral suppository. The product is inserted into the urethra using a single-use applicator. Alprostadil is prostaglandin E1 and produces penile erection through local vasodilation and increased intracellular cyclic AMP.
The U.S. product was approved under NDA 020868. Available strengths are 125, 250, 500, and 1,000 micrograms. The recommended starting dose is generally 500 micrograms, with titration based on response and tolerability. Patients should not use more than two doses in 24 hours or seven doses in seven days.[1]
MUSE differs from oral sildenafil, tadalafil, and vardenafil because it does not depend on gastrointestinal absorption or sexual stimulation to the same degree. Its limitations include urethral discomfort, penile pain, dizziness, hypotension, inconsistent efficacy, and the need for administration shortly before intercourse.
What is the FDA regulatory status of MUSE?
MUSE remains an FDA-approved alprostadil dosage form, although U.S. commercial availability has been constrained and product distribution has varied by period and channel. FDA drug listings distinguish regulatory approval from current commercial supply; an approved NDA can remain in the agency database even when a product is not actively marketed.
| Regulatory item |
MUSE status |
| Active ingredient |
Alprostadil |
| Dosage form |
Urethral suppository |
| U.S. NDA |
020868 |
| Route |
Intraurethral |
| Initial FDA approval |
1990s |
| Strengths |
125, 250, 500, 1,000 mcg |
| FDA exclusivity |
Expired |
| U.S. generic competition |
Limited or absent as a directly substitutable urethral product |
| Regulatory protection today |
Primarily the approved product and brand position, not statutory exclusivity |
The FDA label identifies MUSE as a product for erectile dysfunction in men and includes warnings concerning priapism, hypotension, penile pain, urethral bleeding, and transmission-related risks when used during intercourse with a pregnant partner.[1]
When does MUSE lose exclusivity?
MUSE lost its meaningful U.S. patent and regulatory exclusivity years ago. The core product patents covering alprostadil urethral delivery and related applicator or formulation concepts were filed in the late 1980s and 1990s. Those patent terms generally expired during the 2000s or 2010s, depending on the claim, filing date, patent-term adjustments, and jurisdiction.
The commercial issue is unusual: patent expiry has not produced a large generic substitution wave. The absence of broad generic entry reflects the small market, limited expected return, product-device manufacturing requirements, and the difficulty of building a profitable distribution network for a niche erectile-dysfunction product.
What patents protect MUSE?
Historically relevant patent families covered:
- Urethral delivery of alprostadil for erectile dysfunction.
- Alprostadil suppository composition and dissolution characteristics.
- Applicator design and drug placement in the urethra.
- Dosing and treatment methods for producing an erection.
Public patent records do not support a current, enforceable U.S. blocking patent estate that would provide MUSE with conventional product exclusivity. Any remaining patent risk would be claim-specific and would require review of individual patent families, terminal disclaimers, continuations, and foreign rights.
What is the Orange Book status of MUSE?
The Orange Book is relevant because it identifies FDA-approved drug products and certain patents or exclusivity periods submitted by NDA holders. MUSE has historically appeared as an approved alprostadil urethral product, but the Orange Book does not establish commercial sales, supply continuity, or the economic strength of the brand.
No current Orange Book exclusivity period gives MUSE a material barrier against a competing alprostadil product. The product’s market position therefore depends on manufacturing, distribution, physician familiarity, patient preference, and reimbursement rather than on an unexpired regulatory monopoly.[2]
How did MUSE’s ownership and commercial strategy change?
MUSE originated with Vivus, which developed and commercialized products in erectile dysfunction and related therapeutic areas. Vivus’s portfolio later shifted toward other assets, including Stendra, and MUSE became a mature, non-core product.
Meda Pharmaceuticals became associated with the commercial rights and marketing of MUSE. Mylan’s acquisition of Meda in 2016 transferred the relevant commercial portfolio into Mylan. Mylan subsequently combined with Upjohn to form Viatris in 2020. This sequence placed MUSE within larger portfolios focused on established medicines, generics, and specialty products rather than high-growth branded innovation.[3][4]
| Period |
Commercial context |
| 1990s-early 2000s |
Launch and specialty positioning as a non-oral erectile-dysfunction therapy |
| 2010s |
Mature-product decline amid generic oral PDE5 competition |
| Mid-2010s |
Commercial rights associated with Meda |
| 2016 |
Meda acquired by Mylan |
| 2020 |
Mylan and Upjohn combined to form Viatris |
| 2020s |
Limited public disclosure and reduced strategic visibility |
What is MUSE’s financial trajectory?
MUSE’s financial trajectory is best characterized as mature, declining, and commercially immaterial relative to the revenues of its later corporate owners.
Public filings from the original and successor companies provide limited product-level disclosure. MUSE was not a principal growth driver in the portfolios of Vivus, Meda, Mylan, or Viatris. After ownership transfers, the companies generally grouped established products into broader geographic or therapeutic categories, preventing a reliable current revenue series for MUSE.
The main financial pressures are:
- Oral PDE5 inhibitors became inexpensive generic products.
- Patients generally prefer oral dosing over urethral administration.
- MUSE requires a specialized applicator and controlled manufacturing process.
- The addressable population is limited to patients who cannot use, do not respond to, or do not prefer oral therapy.
- Reimbursement and pharmacy availability can materially affect patient access.
- Marketing investment is difficult to justify for a low-growth product with no patent exclusivity.
The resulting financial profile is a declining cash-flow asset with low incremental research spending. Its value is more likely to come from maintaining supply and extracting residual brand demand than from expanding the erectile-dysfunction market.
How does MUSE compare with Viagra, Cialis, Stendra, and injectable alprostadil?
| Product or class |
Active ingredient |
Administration |
Generic competition |
Commercial position |
| MUSE |
Alprostadil |
Urethral suppository |
Limited direct competition |
Niche, mature |
| Viagra |
Sildenafil |
Oral tablet |
Extensive |
Large generic market |
| Cialis |
Tadalafil |
Oral tablet |
Extensive |
Large generic market, daily-use segment |
| Stendra |
Avanafil |
Oral tablet |
More limited than sildenafil or tadalafil in some markets |
Branded niche |
| Caverject/Edex-type products |
Alprostadil |
Intracavernosal injection |
Product-specific competition |
Effective but invasive |
| Vacuum erection devices |
Mechanical |
External device |
Device market |
Non-drug alternative |
| Penile implants |
Surgical device |
Implantation |
Specialist market |
Durable option for refractory cases |
MUSE’s main competitive advantage is its non-oral local delivery. Its main disadvantage is that it combines the inconvenience of a procedural therapy with lower perceived convenience than injections or oral medicines.
Tadalafil and sildenafil dominate first-line treatment because of low generic pricing, broad physician familiarity, and simple administration. Injectable alprostadil generally has stronger efficacy but requires a needle. MUSE occupies an intermediate position: less invasive than injection, but less convenient and often less reliable than oral treatment.
What generic entry risks exist for MUSE?
Direct generic entry is legally possible because core patent protection has expired. The practical risk is lower than the legal possibility suggests.
A potential competitor would need to address:
- Drug-device combination manufacturing.
- Urethral dosage uniformity.
- Suppository stability and dissolution.
- Applicator performance.
- Human-factors requirements.
- Bioequivalence or comparative clinical expectations.
- Small-volume commercial economics.
- Pharmacy and prescriber adoption.
A generic entrant could reduce price, but the market may be too small to support multiple manufacturers. A lower-priced competitor would also face substitution limits because many patients and physicians may choose oral PDE5 products instead of any urethral alprostadil product.
Have companies challenged MUSE through Paragraph IV litigation?
There is no widely reported, commercially significant Paragraph IV litigation campaign against MUSE comparable to disputes involving major branded drugs. The absence of prominent litigation is consistent with the product’s modest market value and limited direct generic opportunity.
A Paragraph IV filing would need to challenge any currently listed patent claims, but expired core patents would not provide a meaningful basis for a new market-exclusivity dispute. The principal risk to the incumbent is therefore a commercial launch by a low-cost manufacturer, not a major patent settlement event.
What formulation and manufacturing barriers protect MUSE?
MUSE has more technical barriers than a standard oral tablet. The product combines a low-dose prostaglandin with a urethral delivery system. Critical manufacturing variables include:
- Precise low-dose drug loading.
- Product uniformity across individual units.
- Moisture and temperature control.
- Suppository mechanical integrity.
- Controlled release and dissolution.
- Applicator dimensional consistency.
- Packaging that preserves stability.
- Human-factors performance during insertion.
These barriers can delay entry and raise development costs. They do not create durable exclusivity by themselves. Once a competitor establishes a compliant manufacturing process, the barriers become cost and execution constraints rather than legal monopolies.
What licensing deals affect MUSE?
MUSE’s principal commercial history involves corporate portfolio transfers and changes in marketing rights rather than a major current licensing deal. Vivus’s commercialization strategy, Meda’s involvement, Mylan’s acquisition of Meda, and the subsequent Viatris combination are the key ownership events.[3][4]
Public disclosures do not identify a current MUSE transaction that materially changes the product’s competitive outlook. Any existing regional distribution or licensing arrangements would need to be evaluated separately because rights may differ between the United States, Europe, Canada, Latin America, and other markets.
What geographic markets remain relevant?
MUSE’s commercial opportunity is strongest in markets with:
- A sizable erectile-dysfunction treatment population.
- Specialist urology prescribing.
- Reimbursement for non-oral therapies.
- Reliable cold-chain or controlled distribution where required.
- Limited access to injectable alternatives.
- A significant population unable to tolerate PDE5 inhibitors.
The United States remains the most important reference market because of FDA approval and the depth of its erectile-dysfunction treatment market. Europe and other developed markets may support residual demand, but pricing, reimbursement, marketing authorization, and ownership differ by country.
Geographic patent expiry does not guarantee simultaneous generic entry. Local regulatory requirements, national reimbursement, and commercial scale determine whether a competitor launches.
What is the outlook for MUSE revenue and generic launch scenarios?
The base case is continued erosion or low, stable residual sales, with availability determined by portfolio priorities and manufacturing economics. A direct generic could lower prices but would probably expand access only modestly because oral generics remain the preferred alternative.
| Scenario |
Market effect |
Financial implication |
| Continued branded supply |
Stable niche demand |
Low but recurring revenue |
| Supply interruption |
Patients migrate to oral or injectable therapies |
Rapid volume loss and possible brand abandonment |
| Direct generic launch |
Price reduction and partial substitution |
Lower branded revenue; limited market expansion |
| Specialist repositioning |
Focus on PDE5-intolerant or refractory patients |
Potential stabilization, not high growth |
| Portfolio divestiture |
New owner targets niche channels |
Cost reduction and possible supply improvement |
A strategic buyer would likely value MUSE on current cash flow, manufacturing continuity, geographic rights, and customer retention. The asset would not normally command a premium based on patent duration or regulatory exclusivity.
Key Takeaways
- MUSE is a transurethral alprostadil product for erectile dysfunction.
- Its core U.S. patent protection has expired, and no material current exclusivity is evident.
- Direct generic competition remains limited because the market is small and the product-device combination is technically more complex than an oral tablet.
- Generic sildenafil and tadalafil have structurally weakened MUSE’s pricing power and patient demand.
- Ownership moved from Vivus-associated commercialization to Meda, then Mylan, and ultimately Viatris.
- Public filings do not provide a reliable current standalone MUSE revenue series.
- The product is best viewed as a mature niche cash-flow asset with supply and distribution risk.
- The principal commercial threat is low-cost substitution and loss of availability, not a major patent litigation campaign.
FAQs
Is MUSE still available in the United States?
Availability has been inconsistent and may vary by pharmacy, distributor, and period. FDA approval and commercial availability are separate issues.
Is there a generic version of MUSE?
Direct generic alprostadil urethral suppository competition has been limited. Generic injectable alprostadil is not a direct pharmaceutical substitute for the MUSE dosage form.
Can MUSE be substituted for sildenafil?
No. MUSE and sildenafil use different active ingredients, routes of administration, dosing instructions, and clinical profiles. Substitution requires a prescriber’s decision.
Does MUSE have biosimilar risk?
No. MUSE is a chemically synthesized small-molecule product, not a biologic. Biosimilar regulation does not apply. Any competitor would use a generic-drug or drug-device regulatory pathway.
What is the largest remaining value driver for MUSE?
The largest value driver is continued access to a defined population of patients who cannot use or do not respond adequately to oral PDE5 inhibitors. Manufacturing reliability and specialist distribution are more important than patent life.
References
- U.S. Food and Drug Administration. (2018). MUSE (alprostadil) urethral suppository prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Meda AB. (2015). Annual report 2015.
- Viatris Inc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
